Evidence map›Paper›PMID 41050699›Full record

ArticleFrontiers in immunology2025

HLA-DR expression in cytotoxic T lymphocytes: a key to boost the therapeutic potential of T cell-based strategies for breast cancer.

Rute Salvador, Bruna Filipa Correia, Daniela Grosa, Telma Martins, Suelen Cristina Soares Baal, Diana Pereira Saraiva, Sofia Cristóvão-Ferreira, Isabel Lopes Pereira, Cátia Rebelo de Almeida, Rita Fior and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. HLA-II Expression Marks Activated and Clonally Expanded CD8International journal of molecular sciences · 2026
    Article
  3. Broad systemic T cell immunity toFrontiers in immunology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Rute SalvadoriNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa, Lisboa, Portugal.
Bruna Filipa CorreiaiNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa, Lisboa, Portugal.
Daniela GrosaiNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa, Lisboa, Portugal.
Telma MartinsHospital Professor Doutor Fernando Fonseca, EPE, Unidade Local de Saúde Amadora/Sintra, Amadora, Portugal.
Suelen Cristina Soares BaalDepartamento de Genética, Universidade Federal do Paraná, Curitiba, PR, Brazil.
Diana Pereira SaraivaiNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa, Lisboa, Portugal.
Sofia Cristóvão-FerreiraInstituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal.
Isabel Lopes PereiraInstituto CUF de Oncologia, Lisboa, Portugal.
Cátia Rebelo de AlmeidaChampalimaud Centre for the Unknown, Champalimaud Foundation, Lisboa, Portugal.
Rita FiorChampalimaud Centre for the Unknown, Champalimaud Foundation, Lisboa, Portugal.
Antonio JacintoiNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa, Lisboa, Portugal.
Carolina MathiasDepartamento de Genética, Universidade Federal do Paraná, Curitiba, PR, Brazil.
Sofia BragaHospital Professor Doutor Fernando Fonseca, EPE, Unidade Local de Saúde Amadora/Sintra, Amadora, Portugal.
M Guadalupe CabraliNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa, Lisboa, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cell-based therapies, involving

Indexed as

Breast NeoplasmsHLA-DR AntigensT-Lymphocytes, CytotoxicAnimalsCell Line, TumorCytotoxicity, ImmunologicFemaleHumansLymphocyte ActivationLymphocytes, Tumor-InfiltratingMiceHLA-DR Antigens3D co-culturesadoptive T cell therapybreast cancercytotoxicitycytotoxic T lymphocytesimmunomodulationimmunotherapy

Identifiers

PMID41050699
PMCPMC12491829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.